Reata Pharmaceuticals downgraded by SVB Leerink with a new price target
$RETA
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Leerink downgraded Reata Pharmaceuticals from Outperform to Market Perform and set a new price target of $35.00 from $282.00 previously